Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adenovirus Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

NCT00119873
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
3
States / cities
San Francisco, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 24, 2026, 12:24 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

NCT05271318
View directory record Official record
Conditions
Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Interventions
TILT-123, pembrolizumab, pegylated liposomal doxorubicin
Biological · Drug
Lead sponsor
TILT Biotherapeutics Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 1 Interventional

Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)

NCT01070797
View directory record Official record
Conditions
Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant
Interventions
Multi-virus Specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

NCT01397708
View directory record Official record
Conditions
Melanoma
Interventions
INXN-2001, INXN-1001
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Park Ridge, Illinois • Goshen, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Not applicable Interventional

Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears

NCT00266734
View directory record Official record
Conditions
Acute Conjunctivitis, Adenoviral Conjunctivitis
Interventions
RPS Adeno Detector
Device
Lead sponsor
Rapid Pathogen Screening
Industry
Eligibility
1 Month and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Springfield, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 1Phase 2 Interventional

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

NCT00064103
View directory record Official record
Conditions
Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Oropharyngeal Cancer, Tongue Cancer
Interventions
Ad5CMV-p53 gene, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer

NCT00003450
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Ad5CMV-p53 gene
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 2 Interventional Results available

Randomized Trial of Suicide Gene Therapy and Prostate Cancer

NCT00583492
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-yCD/mutTKSR39rep-ADP, IMRT
Biological · Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

NCT01143181
View directory record Official record
Conditions
Double-stranded DNA Virus
Interventions
Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Loma Linda, California • Los Angeles, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Jul 24, 2026, 12:24 AM EDT
Terminated Phase 1 Interventional

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

NCT02231853
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, CML (Chronic Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), Acute Lymphoblastic Leukemia, AML (Acute Myelogenous Leukemia)
Interventions
MVST, MVSTr
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 1 Interventional

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

NCT00709605
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed

NCT00003649
View directory record Official record
Conditions
Lung Cancer
Interventions
Ad5CMV-p53 gene
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
3
States / cities
Nashville, Tennessee • Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 24, 2026, 12:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

NCT03594981
View directory record Official record
Conditions
Viral Infection
Interventions
CMV/AdV /EBV/BKV specific T cells
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection

NCT02087306
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Months and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
33
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jul 24, 2026, 12:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03329248
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin, SBRT
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

NCT02598388
View directory record Official record
Conditions
Hemorrhagic Fever, Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 70 Years
Enrollment
578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 1 Interventional

Intrapleural Gene Transfer for Pleural Mesothelioma

NCT01212367
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
SCH 721015
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 1 Interventional

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

NCT02197169
View directory record Official record
Conditions
Glioblastoma or Gliosarcoma
Interventions
Single intratumoral injection of DNX-2401, Interferon-gamma
Drug
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Jul 24, 2026, 12:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study

NCT01971359
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Jul 24, 2026, 12:24 AM EDT
Not listed Phase 2 Interventional

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

NCT03190824
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage Iv
Interventions
OBP-301
Drug
Lead sponsor
Syneos Health
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

NCT01095224
View directory record Official record
Conditions
HIV Infections
Interventions
rAd35 Env A, rAd5 Env A, rAd5 Env B
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jul 24, 2026, 12:24 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Primary Brain Tumors

NCT00002824
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gene therapy, chemotherapy, ganciclovir, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jul 24, 2026, 12:24 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

NCT07544589
View directory record Official record
Conditions
Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Interventions
DISP-10
Biological
Lead sponsor
Dispatch Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2046
U.S. locations
3
States / cities
Duarte, California • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 24, 2026, 12:24 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

NCT04732468
View directory record Official record
Conditions
Covid19
Interventions
hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
Biological · Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 24, 2026, 12:24 AM EDT